US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.
The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma and assess the safety and efficacy of the combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
“YH001 was discovered using Biocytogen’s evidence-based in vivo drug efficacy screening platform and has demonstrated a favorable safety profile and promising anti-tumor activity in combination with a PD-1 antibody in an earlier phase 1 clinical study,” said Rong Chen, M.D., Ph.D., VP of Biocytogen, CEO and CMO of Eucure Biopharma. “As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy. We are glad to learn that the combination therapy of YH001 + envafolimab and doxorubicin received IND approval by the FDA.”
“We are pleased to receive approval from the FDA to initiate our triplet combination therapy study in sarcoma, which includes our potentially best-in-class CTLA-4 antibody YH001 and the only subcutaneous checkpoint inhibitor approved anywhere in the world, envafolimab,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer. “We look forward to enrolling patients in this study and giving patients additional options for their sarcoma treatment.”
About YH001
YH001 is an IgG1 antibody targeting CTLA-4 that was invented by Biocytogen, the parent company of Eucure Biopharma, and licensed by TRACON. YH001 has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab. In preclinical studies YH001 demonstrated superior T cell activation and superior tumor growth inhibition activity compared to ipilimumab as a single agent and when combined with a PD-(L)1 antibody in human transgenic mouse tumor models. In these models, single agent YH001 depleted regulatory T cells and increased CD8+ T cells in tumor tissue. YH001 has been dosed as a single agent in a Phase 1 trial in China (NCT04699929) and in combination with the PD-1 antibody toripalimab in a Phase 1 trial in Australia (NCT04357756).
About Eucure Biopharma
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen’s R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. The company has established a product pipeline for more than 10 targets, with two products in launched phase II multi-regional clinical trials (MRCT) and two in phase I. For details, please visit www.eucure.com.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai and Boston, USA. For more information, please visit www.biocytogen.com.cn.
About TRACON
TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005548/en/
Contact information
Biocytogen
Drug Assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SS&C Expands European Wealth Management Capabilities with New MiFID License in Ireland25.11.2025 14:00:00 EET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced significant expansion of its European wealth management business with the establishment of SS&C Wealth Services Europe Ltd. The business has been granted authorization under the Markets in Financial Instruments Directive (MiFID) by the Central Bank of Ireland. The license strengthens SS&C’s ability to serve the European Union’s wealth management sector. The company can now deliver its full suite of technology-enabled wealth management solutions directly from Ireland. The new operation builds on SS&C’s successful U.K. wealth management business, creating a pan-European platform with advanced technology, deep regulatory expertise, and comprehensive servicing capabilities. Based in Dublin, the business will focus on helping financial institutions modernize and scale their wealth operations through SS&C’s integrated wealth platform, custody, and back-office services. SS&C employs more than 550 professionals in Ireland, servici
A-HEAT Allied Heat Exchange Technology AG mourns CEO Christian Weiser25.11.2025 14:00:00 EET | Press release
With deep sorrow, A-HEAT/Güntner announces the sudden and unexpected passing of Christian Weiser, CEO of A-HEAT Allied Heat Exchange Technology AG (A-HEAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125106542/en/ Christian Weiser “We have lost a truly remarkable person. Christian Weiser was a leader of integrity, empathy, and humor. His tireless commitment helped to make the A-HEAT Group what it is today,” said Hubert Spegel, Member of the Board at A-HEAT. “Our thoughts and deepest sympathy go to his family, his loved ones, and all those who worked with him. We will honor his legacy and strive to continue his work with the same passion and conviction.” Throughout his decades-long career within the group, Christian Weiser held numerous leadership positions before being appointed CEO of A-HEAT. Under his leadership, the A-HEAT/Güntner Group expanded its global presence, strengthened its innovation and sustainability in
HCLTech Signs Strategic Collaboration Agreement With AWS to Accelerate Financial Services Industry Transformation With AI and Core Modernization25.11.2025 12:30:00 EET | Press release
HCLTech, a leading global technology company, today announced that it has signed a strategic collaboration agreement with Amazon Web Services (AWS) to accelerate innovation in the financial services industry through autonomous, AI-powered solutions. The collaboration brings together HCLTech’s deep domain expertise and AWS to deliver transformative outcomes for financial services organizations. “We understand that a digital journey is of strategic importance and the need of the hour is for a trusted partner that can engage across the transformation lifecycle,” said Srinivasan Seshadri, Chief Growth Officer and Global Head of Financial Services at HCLTech. “Financial institutions face increasing pressure to modernize their systems, deliver exceptional customer experiences, and meet sustainability requirements and many struggle with legacy infrastructure, siloed data, and complex regulatory requirements. Our collaboration with AWS addresses these challenges by providing proven solutions a
Bridgepoint to Partner With ht.digital, the Leading Digital Asset Transparency Layer25.11.2025 10:00:00 EET | Press release
Bridgepoint, one of the world’s leading mid-market investors, today announced that it has agreed to acquire a majority stake in ht.digital, a leading, London-headquartered provider of digital asset assurance and technology solutions. The investment will be made by Bridgepoint Development Capital V – Bridgepoint’s lower middle-market fund focused on supporting fast-growing businesses across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125907148/en/ Digital assets – including cryptocurrencies, stablecoins and tokenised financial instruments, all built upon blockchain technology – are an increasingly important part of the global financial system. As adoption accelerates, regulation is driving vast demand for independent, institutional-grade assurance services to strengthen transparency and safeguard investors. ht.digital is the leading digital asset transparency layer. From proof of reserves and attestations to fin
Thredd Signs Landmark Agreement to Enable Visa Cloud Connect Globally25.11.2025 10:00:00 EET | Press release
Thredd, a leading next-generation global payments processor, today announced that it has signed an agreement to enable Visa Cloud Connect on a global scale. This milestone reflects Thredd’s continued investment in cloud-first infrastructure and reinforces its role as a global technology leader in payments processing. Visa Cloud Connect allows organisations to access VisaNet, Visa’s secure and powerful global payments network, through their own cloud-based infrastructure. Purpose-built for cloud-native clients, Visa Cloud Connect can help deliver increased flexibility, faster time to market, and seamless scalability across borders. Under the agreement, Thredd will connect across three global Visa Cloud Connect endpoints, committing to a full global rollout. Once live, this will eliminate the need for multiple regional integrations, helping our clients gain new geographies and accelerating Thredd’s vision of a unified global processing platform. "Signing this agreement is about future-pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom